Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 163


A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.

Kong LR, Mohamed Salleh NAB, Ong RW, Tan TZ, Syn NL, Goh RM, Fhu CW, Tan DSW, Iyer NG, Kannan S, Verma CS, Lim YC, Soo R, Ho J, Huang Y, Lim JSJ, Yan BJ, Nga ME, Lim SG, Koeffler HP, Lee SC, Kappei D, Hung HT, Goh BC.

Nat Commun. 2020 Mar 25;11(1):1556. doi: 10.1038/s41467-020-15318-5.


Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors.

Chin TM, Boopathy GTK, Man EPS, Clohessy JG, Csizmadia E, Quinlan MP, Putti T, Wan SC, Xie C, Ali A, Wai FC, Ong YS, Goh BC, Settleman J, Hong W, Levantini E, Tenen DG.

Theranostics. 2020 Feb 3;10(6):2727-2743. doi: 10.7150/thno.38729. eCollection 2020.


Elevated IL18 levels in Nasopharyngeal carcinoma induced PD-1 expression on NK cells in TILS leading to poor prognosis.

Liou AK, Soon G, Tan L, Peng Y, Cher BM, Goh BC, Wang S, Lim CM.

Oral Oncol. 2020 Mar 6;104:104616. doi: 10.1016/j.oraloncology.2020.104616. [Epub ahead of print]


Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer.

Ngoi NYL, Choong C, Lee J, Bellot G, Wong ALA, Goh BC, Pervaiz S.

Cancers (Basel). 2020 Mar 2;12(3). pii: E574. doi: 10.3390/cancers12030574. Review.



Chong QY, Kok ZH, Bui NL, Xiang X, Li-Ann Wong A, Peng Yong W, Sethi G, Lobie PE, Wang L, Goh BC.

Pharmacol Res. 2020 Feb 14:104686. doi: 10.1016/j.phrs.2020.104686. [Epub ahead of print] Review.


Targeting Cell Metabolism as Cancer Therapy.

Ngoi NYL, Eu JQ, Hirpara J, Wang L, Lim JSJ, Lee SC, Lim YC, Pervaiz S, Goh BC, Wong ALA.

Antioxid Redox Signal. 2020 Feb 10;32(5):285-308. doi: 10.1089/ars.2019.7947. Epub 2019 Dec 16.


A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma.

Zhang M, Wang B, Chong QY, Pandey V, Guo Z, Chen RM, Wang L, Wang Y, Ma L, Kumar AP, Zhu T, Wu ZS, Yin Z, Basappa, Goh BC, Lobie PE.

Oncogenesis. 2019 Nov 4;8(11):65. doi: 10.1038/s41389-019-0173-8.


Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators.

Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Erratum in: Lancet. 2020 Jan 25;395(10220):272. Lancet. 2020 Feb 22;395(10224):564.


MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma.

Li B, Yan J, Phyu T, Fan S, Chung TH, Mustafa N, Lin B, Wang L, Eichhorn PJA, Goh BC, Ng SB, Kappei D, Chng WJ.

Blood. 2019 Dec 5;134(23):2046-2058. doi: 10.1182/blood.2019000381.


Population diversity in oncology drug responses and implications to drug development.

Walsh R, Goh BC.

Chin Clin Oncol. 2019 Jun;8(3):24. doi: 10.21037/cco.2019.05.01.


FBXW5 Promotes Tumorigenesis and Metastasis in Gastric Cancer via Activation of the FAK-Src Signaling Pathway.

Yeo MS, Subhash VV, Suda K, Balcıoğlu HE, Zhou S, Thuya WL, Loh XY, Jammula S, Peethala PC, Tan SH, Xie C, Wong FY, Ladoux B, Ito Y, Yang H, Goh BC, Wang L, Yong WP.

Cancers (Basel). 2019 Jun 17;11(6). pii: E836. doi: 10.3390/cancers11060836.


PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q.

Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x.


Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential.

Varughese RS, Lam WS, Marican AABH, Viganeshwari SH, Bhave AS, Syn NL, Wang J, Wong AL, Kumar AP, Lobie PE, Lee SC, Sethi G, Goh BC, Wang L.

Cancer. 2019 Jun 1;125(11):1789-1798. doi: 10.1002/cncr.32069. Epub 2019 Apr 1. Review.


Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma.

Chen Y, Xu L, Mayakonda A, Huang ML, Kanojia D, Tan TZ, Dakle P, Lin RY, Ke XY, Said JW, Chen J, Gery S, Ding LW, Jiang YY, Pang A, Puhaindran ME, Goh BC, Koeffler HP.

Nat Commun. 2019 Mar 22;10(1):1353. doi: 10.1038/s41467-019-09257-z.


Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance.

Hirpara J, Eu JQ, Tan JKM, Wong AL, Clement MV, Kong LR, Ohi N, Tsunoda T, Qu J, Goh BC, Pervaiz S.

Redox Biol. 2019 Jul;25:101076. doi: 10.1016/j.redox.2018.101076. Epub 2018 Dec 17.


Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors.

Lee M, Hirpara JL, Eu JQ, Sethi G, Wang L, Goh BC, Wong AL.

Redox Biol. 2019 Jul;25:101073. doi: 10.1016/j.redox.2018.101073. Epub 2018 Dec 13. Review.


Role of tumor-derived exosomes in cancer metastasis.

Wee I, Syn N, Sethi G, Goh BC, Wang L.

Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):12-19. doi: 10.1016/j.bbcan.2018.10.004. Epub 2018 Nov 9. Review.


A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs.

Wong AL, Xiang X, Ong PS, Mitchell EQY, Syn N, Wee I, Kumar AP, Yong WP, Sethi G, Goh BC, Ho PC, Wang L.

Pharmaceutics. 2018 Nov 8;10(4). pii: E221. doi: 10.3390/pharmaceutics10040221. Review.


A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study.

Wang L, Phan DK, Syn N, Xiang X, Song H, Thuya WL, Yang S, Wong AL, Kumar AP, Yong WP, Sethi G, Ho PC, Goh BC.

Pharmaceutics. 2018 Aug 8;10(3). pii: E123. doi: 10.3390/pharmaceutics10030123.


Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial.

Syn NL, Wong AL, Lee SC, Teoh HL, Yip JWL, Seet RC, Yeo WT, Kristanto W, Bee PC, Poon LM, Marban P, Wu TS, Winther MD, Brunham LR, Soong R, Tai BC, Goh BC.

BMC Med. 2018 Jul 10;16(1):104. doi: 10.1186/s12916-018-1093-8.

Supplemental Content

Loading ...
Support Center